The UK competition authority CMA, found violation in the antidepressant drug investigation against 4 pharmaceutical companies; King, Auden Mckenzie, Alissa and Lexon.
The Authority found that Auden Mckenzie and King agreed as follows: Auden Mckenzie would supply only 10mg nortriptyline tablets, while King would supply only 25mg nortriptyline tablets in 2014 and two companies also agreed to fix the quantities and prices. The Authority also found that, King, Alissa and Lexon exchanged commercially sensitive information such as prices, volumes and entry plans in order to keep Nortriptyline prices high.
Based on these findings, CMA fined all four companies. In addition, CMA ordered disqualification of a company executive for 7 years and is also considering the possible disqualification of other directors.
(CMA Decision – 04.03.2020)